Filtered By:
Cancer: Prostate Cancer

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 222 results found since Jan 2013.

SNMMI 2020: AI analysis of PET could help classify prostate cancer
An artificial intelligence (AI) algorithm may be able to assist in classifying...Read more on AuntMinnie.comRelated Reading: SNMMI 2020: PET/MRI combo tracks osteoarthritis progression SNMMI 2020: PSMA-PET/CT changes prostate cancer management SNMMI 2020: PET tracer could image, treat glioblastoma SNMMI 2020: PET radiotracer measures stroke recovery SNMMI 2020: AI can aid in diagnosis of Parkinson's disease
Source: AuntMinnie.com Headlines - July 17, 2020 Category: Radiology Source Type: news

Gonadotropin-releasing hormone agonists, anti-androgens and the risk of cardio-cerebrovascular disease in prostate cancer patients: an asian population-based observational study
Conclusions: The current study based on Asian population suggests that treatment with neither GnRH agonist nor antiandrogens increases the risk of cardio-cerebrovascular disease compared to patients with ADT-naïve prostate cancer.
Source: Journal of Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Jong-Mi Seong, Dongho Shin, Jae Woo Sung, Shinjay Cho, Jonghyup Yang, Sungmin Kang, Hyong Woo Moon, Kyu Won Lee, U-Syn Ha Tags: Research Paper Source Type: research

Prostate Cancer Drug Could Be 'Game Changing'
For men with advanced prostate cancer, a new hormone therapy pill works better than standard injections -- and carries a much lower risk of heart attack or stroke.
Source: WebMD Health - May 29, 2020 Category: Consumer Health News Source Type: news

Prostate Cancer Drug Could Be ' Game Changing, ' Researchers Say
FRIDAY, May 29, 2020 -- For men with advanced prostate cancer, a new hormone therapy pill works better than standard injections -- and carries a much lower risk of heart attack or stroke, a clinical trial has found. The drug, called relugolix, is...
Source: Drugs.com - Daily MedNews - May 29, 2020 Category: General Medicine Source Type: news

Co-morbidities in a Retrospective Cohort of Prostate Cancer Patients.
Conclusion: Better chronic disease management is needed among prostate cancer survivors through more effective survivorship care planning and interventions that promote health behaviors. PMID: 32269460 [PubMed - in process]
Source: Ethnicity and Disease - April 11, 2020 Category: International Medicine & Public Health Tags: Ethn Dis Source Type: research

In memoriam: Haines Ely, MD, FAAD
Aside from the news about the canceling of the American Academy of Dermatology Annual Meeting in Denver, there is horrible news that is difficult with every key stroke as I write today …Dr Haines Ely, long-standing pinnacle member of Noah Worcester, Pacific Dermatologic Association, RxDerm, and the American Academy of Dermatology, has passed away after a long battle with prostate cancer. He is survived by his wife, Jenny, and adult daughters, Meredith Bordoni (Michael), Rebecca Ely, and Tess Ely.
Source: Journal of the American Academy of Dermatology - March 12, 2020 Category: Dermatology Authors: Neal Bhatia Tags: In memoriam Source Type: research

Omega-3 fats do not protect against cancer
(University of East Anglia) Omega-3 fats do not protect against cancer -- according to new University of East Anglia research. Increased consumption of omega-3 fats is widely promoted globally because of a common belief that it will protect against, or even reverse, diseases such as cancer, heart attacks and stroke. But two systematic reviews find that omega-3 supplements may slightly reduce coronary heart disease mortality and events, but slightly increase risk of prostate cancer. Both beneficial and harmful effects are small.
Source: EurekAlert! - Cancer - February 28, 2020 Category: Cancer & Oncology Source Type: news

“One stroke, with twenty-two people”: exploring prostate cancer survivors' participation in dragon boating
.
Source: Journal of Psychosocial Oncology - February 16, 2020 Category: Cancer & Oncology Authors: Isabella V. Cin à Katie M. Di Sebastiano Guy E. Faulkner Source Type: research

To the Horizon: The Brink of an AI Revolution in Prostate Cancer?
Noorbakhsh-Sabet et al.1 published an excellent review in The American Journal of Medicine summarizing the potential of artificial intelligence (AI) in medicine. They describe wide utility (e.g. in dermatology and stroke), but do not consider surgery and urology, which embrace cutting-edge technology, including fusion-biopsy and robotics,2 and will be early AI adopters. Indeed, prostate cancer creates a huge health care burden, thus being ideal for AI transformation.
Source: The American Journal of Medicine - January 16, 2020 Category: General Medicine Authors: Joseph M. Norris, Asif Raza Tags: Letter Source Type: research

Cancers, Vol. 12, Pages 189: Influence of Baseline Cardiovascular Comorbidities on Mortality after Androgen Deprivation Therapy for Metastatic Prostate Cancer
ih Shao Few studies have assessed the benefits of androgen deprivation therapy (ADT) in men with metastatic prostate cancer (PC; mPC) at an old age or with major cardiovascular conditions. A retrospective cohort consisted of 3835 men with newly diagnosed mPC from the Taiwan Cancer Registry of 2008–2014. Among them, 2692 patients received only ADT in the first year after the cancer diagnosis, and 1143 patients were on watchful waiting. The inverse probability of treatment-weighted Cox model was used to estimate the effects of ADT on all-cause mortality and PC-specific mortality according to age, and the...
Source: Cancers - January 11, 2020 Category: Cancer & Oncology Authors: Wu Fang Hwang Shih Shao Tags: Article Source Type: research

U.S. Cancer Death Rates Continue to Drop, But Progress Is Stalling for Some Cancers
Over the last few decades, the death rate from cancer dropped by 29% in the U.S., according to the latest data from the American Cancer Society (ACS). That, the ACS’s new study estimates, saved 2.9 million lives from 1991 to 2017, largely owing to declines in mortality from the four leading cancer types: lung, breast, prostate and colon. From 2016 to 2017—the latest year for which data are available—the overall cancer death rate declined by 2.2%, the largest single-year reduction ever recorded. These new figures were reported in a study published in CA: A Cancer Journal for Clinicians. The declines are a...
Source: TIME: Health - January 8, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer Source Type: news

Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan
Androgen deprivation therapy (ADT) in the treatment of prostate cancer may be associated with an increased risk of thromboembolic disease. The aim of our study was to investigate the association of ADT in the ...
Source: BMC Cancer - December 30, 2019 Category: Cancer & Oncology Authors: Kuang-Ming Liao, Yaw-Bin Huang, Chung-Yu Chen and Chen-Chun Kuo Tags: Research article Source Type: research

Pharmacological treatment of NASH.
Abstract Lifestyle modifications, especially weight loss, are efficient on NASH liver injury, however rarely followed in clinical practice. The target population of pharmacologic treatments is represented by patients with NASH and fibrosis. Out of histological improvement, efficacy of treatments should be assessed through liver morbi-mortality benefit, but also on extrahepatic events, such as cardiovascular. Among anti-diabetic treatments, glitazones et GLP-1 agonists have shown efficacy on histological liver injury. Vitamin E is efficient on liver injury but at the cost of prostate cancer and stroke over risk. Ab...
Source: Presse Medicale - November 18, 2019 Category: General Medicine Authors: Serfaty L Tags: Presse Med Source Type: research

N-acetylaspartylglutamate (NAAG) and Glutamate Carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications
Publication date: Available online 12 November 2019Source: Progress in NeurobiologyAuthor(s): Joseph H. Neale, Tatsuo YamamotoAbstractN-Acetylaspartylglutamate (NAAG) is the third most prevalent neurotransmitter in the mammalian nervous system, yet its therapeutic potential is only now being fully recognized. Drugs that inhibit the inactivation of NAAG by glutamate carboxypeptidase II (GCPII) increase its extracellular concentration and its activation of its receptor, mGluR3. These drugs warrant attention, as they are effective in animal models of several clinical disorders including stroke, traumatic brain injury and schi...
Source: Progress in Neurobiology - November 13, 2019 Category: Neuroscience Source Type: research

Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases
In this study, we used large-scale electronic health records data from multiple linked UK databases to address these evidence gaps.MethodsFor this population-based cohort study, we used linked primary care, hospital, and cancer registry data from the UK Clinical Practice Research Datalink to identify cohorts of survivors of the 20 most common cancers who were 18 years or older and alive 12 months after diagnosis and controls without history of cancer, matched for age, sex, and general practice. We compared risks for a range of cardiovascular disease outcomes using crude and adjusted Cox models. We fitted interactions to in...
Source: The Lancet - August 21, 2019 Category: General Medicine Source Type: research